一种评估人体内血管紧张素转换酶抑制剂效力的方法。
A method for estimating the potency of angiotensin-converting enzyme inhibitors in man.
作者信息
Wellstein A, Essig J, Belz G G
机构信息
Institut für Kardiovaskuläre Therapie, Wiesbaden, Federal Republic of Germany.
出版信息
Br J Clin Pharmacol. 1987 Sep;24(3):397-9. doi: 10.1111/j.1365-2125.1987.tb03188.x.
Abstract
Dose-response curves of the effect of angiotensin I (A-I) infusion on diastolic blood pressure were constructed before and 3 h following single oral doses of the angiotensin-converting enzyme (ACE) inhibitor cilazapril (1.25 to 30 mg) in six normal male subjects. Cilazapril shifted the A-I dose-response curves dose dependently rightward; Schild-plot analysis indicated a competitive antagonism by cilazapril with an apparent Ki-dose of about 0.6 mg.
摘要
在6名正常男性受试者中，分别于单次口服血管紧张素转换酶（ACE）抑制剂西拉普利（1.25至30毫克）之前及之后3小时，构建了输注血管紧张素I（A-I）对舒张压影响的剂量-反应曲线。西拉普利使A-I剂量-反应曲线剂量依赖性地向右移动；希尔德分析表明西拉普利具有竞争性拮抗作用，其表观Ki剂量约为0.6毫克。
相似文献
1
A method for estimating the potency of angiotensin-converting enzyme inhibitors in man.一种评估人体内血管紧张素转换酶抑制剂效力的方法。
Br J Clin Pharmacol. 1987 Sep;24(3):397-9. doi: 10.1111/j.1365-2125.1987.tb03188.x.
2
The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.人在接受血管紧张素I激发后血管紧张素转换酶（ACE）活性的评估：西拉普利、卡托普利和依那普利的比较
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):217S-223S. doi: 10.1111/j.1365-2125.1989.tb03485.x.
3
Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril.正常志愿者对血管紧张素I的血流动力学反应以及血管紧张素转换酶抑制剂西拉普利的拮抗作用。
J Cardiovasc Pharmacol. 1987 Feb;9(2):219-24. doi: 10.1097/00005344-198702000-00015.
4
Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers.
Clin Pharmacol Ther. 1987 Jun;41(6):639-44. doi: 10.1038/clpt.1987.89.
5
Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.西拉普利抑制ACE对人体内脏和全身血流动力学的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):225S-234S. doi: 10.1111/j.1365-2125.1989.tb03486.x.
6
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31.
7
Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.西拉普利以及西拉普利与普萘洛尔联合用药的临床药效学研究。
Drugs. 1991;41 Suppl 1:11-7. doi: 10.2165/00003495-199100411-00004.
8
Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.健康男性中西拉普利血浆浓度与血流动力学及激素效应之间的相关性。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):189S-197S. doi: 10.1111/j.1365-2125.1989.tb03481.x.
9
A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.新型血管紧张素转换酶抑制剂西拉普利的临床前心血管药理学综述。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. doi: 10.1111/j.1365-2125.1989.tb03475.x.
10
Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.西拉普利与普萘洛尔在人体中的相互作用；血浆药物浓度、激素和酶反应、血流动力学、激动剂剂量效应曲线及压力感受器反射。
Br J Clin Pharmacol. 1988 Nov;26(5):547-56. doi: 10.1111/j.1365-2125.1988.tb05294.x.
引用本文的文献
1
Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.用于临床药理学中不同血管紧张素II AT1受体拮抗剂特性表征的血管紧张素II剂量效应曲线和希尔德回归图。
Br J Clin Pharmacol. 2003 Jul;56(1):3-10. doi: 10.1046/j.1365-2125.2003.01880.x.
2
Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.坎地沙坦在人体中的血管紧张素II拮抗作用及血浆放射受体动力学
Br J Clin Pharmacol. 1998 Jun;45(6):567-73. doi: 10.1046/j.1365-2125.1998.00722.x.
3
Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.西拉普利与普萘洛尔在人体中的相互作用；血浆药物浓度、激素和酶反应、血流动力学、激动剂剂量效应曲线及压力感受器反射。
Br J Clin Pharmacol. 1988 Nov;26(5):547-56. doi: 10.1111/j.1365-2125.1988.tb05294.x.
4
Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.血管紧张素转换酶抑制剂。药效学与药代动力学之间的关系。
Clin Pharmacokinet. 1988 Nov;15(5):295-318. doi: 10.2165/00003088-198815050-00003.
5
The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.人在接受血管紧张素I激发后血管紧张素转换酶（ACE）活性的评估：西拉普利、卡托普利和依那普利的比较
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):217S-223S. doi: 10.1111/j.1365-2125.1989.tb03485.x.
6
Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients.血管紧张素转换酶抑制剂西拉普利与β-肾上腺素能受体拮抗剂普萘洛尔在健康受试者和高血压患者中的药代动力学和药效学相互作用。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):317S-322S. doi: 10.1111/j.1365-2125.1989.tb03498.x.
7
Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.在健康受试者和高血压患者中，西拉普利与普萘洛尔相比的血流动力学和激素效应。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):309S-315S. doi: 10.1111/j.1365-2125.1989.tb03497.x.
8
Apparent racial difference in response to angiotensin I infusion.
Eur J Clin Pharmacol. 1990;39(2):183-5. doi: 10.1007/BF00280056.
9
Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.
Drugs. 1991 May;41(5):799-820. doi: 10.2165/00003495-199141050-00008.
10
Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.西拉普利以及西拉普利与普萘洛尔联合用药的临床药效学研究。
Drugs. 1991;41 Suppl 1:11-7. doi: 10.2165/00003495-199100411-00004.
本文引用的文献
1
Some quantitative uses of drug antagonists.药物拮抗剂的一些定量应用。
Br J Pharmacol Chemother. 1959 Mar;14(1):48-58. doi: 10.1111/j.1476-5381.1959.tb00928.x.
2
Theories of drug antagonism.药物拮抗作用理论。
Pharmacol Rev. 1957 Jun;9(2):211-8.
3
A modification of receptor theory.受体理论的一种修正。
Br J Pharmacol Chemother. 1956 Dec;11(4):379-93. doi: 10.1111/j.1476-5381.1956.tb00006.x.
4
The design of a new group of angiotensin-converting enzyme inhibitors.
FEBS Lett. 1982 Oct 18;147(2):175-9. doi: 10.1016/0014-5793(82)81036-3.
5
Enzymes of the renin-angiotensin system and their inhibitors.肾素-血管紧张素系统的酶及其抑制剂。
Annu Rev Biochem. 1982;51:283-308. doi: 10.1146/annurev.bi.51.070182.001435.
6
Characterization of angiotensin converting enzyme by [3H]captopril binding.通过[3H]卡托普利结合对血管紧张素转换酶进行表征。
Mol Pharmacol. 1986 Feb;29(2):142-8.
7
Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.普萘洛尔的受体结合是人体血浆浓度动力学与效应时程之间缺失的环节。
Eur J Clin Pharmacol. 1985;29(2):131-47. doi: 10.1007/BF00547412.
8
[Cilazapril in essential hypertension. A placebo-controlled double-blind study to establish the dosage].
Med Klin (Munich). 1986 Jul 18;81(15-16):524-9.
9
Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril.正常志愿者对血管紧张素I的血流动力学反应以及血管紧张素转换酶抑制剂西拉普利的拮抗作用。
J Cardiovasc Pharmacol. 1987 Feb;9(2):219-24. doi: 10.1097/00005344-198702000-00015.
10
Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
J Cardiovasc Pharmacol. 1985 May-Jun;7(3):569-80. doi: 10.1097/00005344-198505000-00025.
Zotero 插件